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on quality of life. Although the underlying 
origin is often unknown, it may be associ-
ated with numerous dermatological, sys-
temic and/or psychological diseases. Given 
its chronicity and relapsing nature, treat-
ment of chronic pruritus with prurigo can 
be challenging. Temporary relief can be 
achieved by use of corticosteroids, topical 
calcineurin inhibitors, menthol, capsaicin 
creams or ultraviolet therapy. Treatment 
with oral agents such as ciclosporin, anxio-
lytics, opiate receptor antagonists, thalido-
mide and gabapentin can be satisfactory; 
however, their pronounced toxicity pre-
vents the long-term use of these drugs, and 
the severity of the disease often worsens 
markedly after treatment has been stopped. 
We present a case of a patient suffering 
from chronic itch with concomitant pru-
rigo and psoriasis lesions successfully treat-
ed with alitretinoin. 
 Case Report 
 A 46-year-old Caucasian woman, with 
a history of plaque psoriasis of the elbows 
and knees, chronic alcohol abuse and de-
pression was admitted to our outpatient 
clinic with severe, 5-year pruritus and sec-
ondary prurigo lesions on the extensor sur-
face of her arms and legs ( fig. 1 a, b). Physi-
cal examination of the patient, blood chem-
istry test, chest X-ray, as well as direct and 
indirect immunofluorescence did not con-
firm any underlying systemic disease. His-
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 Abstract 
 Background: Chronic itch with secondary 
scratch lesions such as prurigo has a major 
impact on quality of life. Due to its relapsing 
nature and often unknown origin, its treat-
ment is challenging.  Objective: We sought to 
demonstrate that alitretinoin can be an ef-
ficacious and well-tolerated treatment in a 
patient suffering from chronic itch with
concomitant prurigo and psoriatic lesions. 
 Methods: Case report.  Results: After 1 month 
of alitretinoin treatment (30 mg daily), itch as 
well as prurigo and psoriasis lesions de-
creased markedly. Three cycles of alitretin-
oin were administered, as each cessation of 
treatment led to relapse of the symptoms af-
ter 6–8 weeks. Tapering of the alitretinoin 
dose (30 mg every second day) after the third 
cycle allowed to maintain the effects for over 
18 months.  Conclusion: Treatment of refrac-
tory prurigo with alitretinoin might be an ef-
ficacious alternative to standard therapies. In 
case of relapse, retreatment with alitretinoin 
reinduces a further long-lasting response. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Chronic pruritus presenting with sec-
ondary scratch lesions such as prurigo has 
been demonstrated to have a major impact 
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tological examination of a skin biopsy of a 
nodular lesion was consistent with prurigo. 
 Previous treatments including topical 
corticosteroids, topical tacrolimus, men-
thol, phototherapy, antihistamines, mon-
telukast, doxepin and gabapentin did not 
provide healing of the lesions. Treatment 
with ciclosporin (200 mg daily) led to sig-
nificant improvement of both prurigo and 
psoriatic lesions (body surface area: 3%), 
but due to a potential risk of long-term ad-
verse reactions the treatment was inter-
rupted after 1 year.
 Eventually, successful treatment with 
alitretinoin (30 mg daily) was introduced. 
After approximately 1 month, pruritus de-
creased and both prurigo and psoriasis le-
sions (body surface area: <1%) improved 
significantly ( fig. 1 c, d). After 5 months, the 
skin lesions healed completely with some 
postinflammatory pigmentations and scars 
( fig. 1 e, f). Consequently, alitretinoin was 
stopped. Altogether 3 cycles of alitretinoin 
were administered, as each cessation of ret-
inoid treatment led to relapse of the symp-
toms after approximately 6–8 weeks. Ta-
pering of the alitretinoin dose (30 mg every 
second day) after the third cycle allowed
to maintain the therapeutic effect for over 
18 months. In the last 3 months treatment 
with alitretinoin 30 mg was extended to ev-
ery third day and no relapse has been ob-
served so far. Treatment was well tolerat-
ed except for a slightly elevated level of 
nonfasting total cholesterol values (up to
7 mmol/l, normal value: <5.2 mmol/l).
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 Discussion 
 Alitretinoin (9- cis -retinoic acid) is a 
novel vitamin A derivate that binds to all 6 
retinoid receptors (retinoic acid receptors 
RAR-α, -β, -γ and retinoid X receptors 
RXR-α, -β, -γ). The most frequent retinoid 
receptor in the skin is RAR-γ/RXR-α het-
erodimer  [1] . Previously used retinoids 
(such as acitretin and etretinate) target 
mainly RAR receptors. Hence, alitretinoin 
is expected to act in a wider spectrum of 
diseases and on different pathways com-
pared to the old retinoids. It has anti-in-
flammatory and immunomodulating ef-
fects and has been demonstrated to regu-
late the production of cytokine and leuko-
cyte activity  [2] . 
 The most frequent adverse effects of ali-
tretinoin include mucocutaneous dryness 
and headache  [3] . The latter is dose depen-
dent and often disappears with dose reduc-
tion. Laboratory abnormalities comprise 
the typical effects of retinoids such as in-
crease in serum lipids and liver enzymes, as 
well as a reduced thyroid-stimulating hor-
mone level. In our case, except for a slight-
ly elevated level of nonfasting total choles-
terol there was no change in the laboratory 
investigations, especially no increase in liv-
er values was observed. Furthermore, the 
mood of the patient was not altered during 
the therapy. 
 Alitretinoin has been registered as a sys-
temic treatment for severe chronic hand 
eczema unresponsive to potent topical cor-
ticosteroids  [4, 5] . In addition to its ap-
proved use, alitretinoin has been reported 
to be beneficial also in refractory pityriasis 
rubra pilaris  [6] , lichen planus  [7, 8] , cuta-
neous lupus erythematosus  [9] , palmo-
plantar pustular psoriasis  [10] as well as in 
mycosis fungoides  [11] , but it appeared to 
have a mixed effect in congenital ichthyosis 
 [12] . Several studies have also been carried 
out with alitretinoin used in the treatment 
of AIDS-related Kaposi’s sarcoma  [13] .
 The present report describes a case of 
chronic itch with secondary prurigo lesions 
and psoriasis successfully treated with ali-
tretinoin (30 mg daily). After approximate-
ly 1 month of the therapy, pruritus de-
creased in our patient and both prurigo and 
psoriasis lesions improved. A significant 
decrease in intensity of itch after treatment 
with alitretinoin has already been demon-
strated in the literature. A case report on 2 
patients with mycosis fungoides described 
a cessation of pruritus after 2 months of ali-
tretinoin treatment (30 mg daily), before 
improvement of the skin lesions  [11] . Sim-
ilarly, in 1 patient with lichen planus treat-
ed with alitretinoin (30 mg daily) pruritus 
disappeared after 4 weeks, before all skin 
lesions completely healed  [8] . It is known 
that itch and subsequent repeated scratch-
a
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 Fig. 1. Clinical presentation before ( a ,  b ), and outcome after approximately 1 month ( c ,  d ) and after 5 months 
( e ,  f ) of alitretinoin treatment. 
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ing are major factors responsible for the de-
velopment of prurigo lesions. Reduction of 
itching is therefore one of the main thera-
peutic strategies in this skin pathology. 
 Histological examinations of prurigo 
nodules have demonstrated a characteristic 
cellular pattern found in the majority of 
specimens. It consisted of fibrosis of the 
papillary dermis, an increased number of 
fibroblasts and capillaries, and a superfi-
cial, perivascular or interstitial inflamma-
tory infiltrate of lymphocytes, macro-
phages and also eosinophils and neutro-
phils  [14] . Moreover, it has been shown 
that an accumulation of neuropeptides up-
regulated the production of many proin-
flammatory cytokines [interleukin (IL)-1α, 
IL-1β and IL-8) as well as degranulation of 
an increased number of mast cells with 
subsequent release of histamine. The latter, 
in addition to induction of itch, stimulates 
proliferation of fibroblasts and synthesis of 
collagen. 
 The exact effects of alitretinoin on the 
pathomechanisms of itch and prurigo have 
not been elucidated so far. Apart from its 
well-known immunomodulatory effects 
on keratinocytes  [15] , it may also influence 
fibroblasts  [16] and mast cells. Studies 
show that 9- cis -retinoic acid is able to in-
hibit in vitro the production of human 
mast cells  [17] . Furthermore, in vitro stim-
ulation of human T cells with 9- cis -retinoic 
acid increases the production of IL-4  [18] . 
The latter has been demonstrated to exert a 
potent inhibitory action on growth of mast 
cells  [19] . It has previously been suggested 
that also pruritogenic IL-31 may play a role 
in the pathogenesis of itch in prurigo  [20] . 
Among the sources of this cytokine are 
mast cells  [21] . Based on the studies men-
tioned above, we can hypothesize that ali-
tretinoin can reduce the production of IL-
31 through its inhibitory effect on mast 
cells. 
 Apart from an increased secretion of 
IL-4, in vitro stimulation of human T cells 
with 9- cis -retinoic acid resulted also in 
raised levels of IL-5 and IL-13, and de-
creased levels of interferon-γ, IL-2, IL-
12p70 and tumor necrosis factor-α  [18] . 
The latter and IL-12/IL-23 play an impor-
tant role in the development of psoriasis 
 [22, 23] . Hence, it can explain the positive 
therapeutic effect of alitretinoin not only 
on prurigo, but also on psoriatic lesions in 
our patient. The positive effect of alitre-
tinoin in psoriasis has been described pre-
viously in only few reports. Irla et al.  [10] 
observed 50% improvement in the Palmo-
plantar Psoriasis Area and Severity Index 
score in 100% of patients with palmoplan-
tar pustular psoriasis (n = 7) treated with 
alitretinoin 30 mg daily for 3 months. 
Moreover, they have also observed a sig-
nificant decrease in itch intensity in all 
studied psoriatic patients. 
 After interruption of the therapy with 
alitretinoin, prurigo lesions relapsed in our 
patient within 6–8 weeks. This phenome-
non has already been observed in studies 
on hand eczema. The median time to re-
lapse, defined as recurrence of 75% of ini-
tial signs and symptoms, was 5.5–6.2 
months in the absence of other medica-
tions  [4] . In our case the second and third 
therapeutic course of alitretinoin (30 mg 
daily) was necessary to completely heal the 
skin lesions. This is consistent with the 
data from a recently reported trial on 
chronic hand eczema  [3] . The authors of 
this study demonstrated that alitretinoin at 
the dose of 30 mg daily reinduced response 
in the majority of patients who had re-
lapsed within 6 months following success-
ful treatment with an initial course of ali-
tretinoin. 
 In conclusion, our report shows that 
treatment of refractory prurigo with ali-
tretinoin might be an efficacious alterna-
tive to standard topical and systemic treat-
ments. In case of relapse, retreatment with 
alitretinoin reinduces a further long-last-
ing response. Further clinical studies are 
warranted to confirm efficacy and safety of 
alitretinoin in this disease.
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